Key result
2,3-Diphosphoglycerate (2,3-DPG) inhibited the platelet release reaction and irreversible aggregation of human blood platelets, with more pronounced effects in cases with low hematocrit.
Why the study?
Does 2,3-Diphosphoglycerate inhibit platelet aggregation in human blood platelets?
Does 2,3-Diphosphoglycerate inhibit platelet aggregation in human blood platelets?
2,3-DPG acts as a physiological inhibitor of platelet aggregation, particularly in conditions of low hematocrit, and its effect is potentiated by dipyridamole and vincaminor.
May modulate platelet function in anemia; hypothesis-generating and requires clinical validation before any therapeutic role.
2,3-Diphosphoglycerate (2,3-DPG) may inhibit the platelet release reaction and the irreversible aggregation of human blood platelets induced by adenosine diphosphate, epinephrine, or norepinephrine. The effects of 2,3-DPG on platelet aggregation were more pronounced in cases with low hematocrit (less than 30 percent). Dipyridamole and vincaminor potentiated the antiaggregating effect of 2,3-DPG. Erythocytes (10-3 to 10-4 per microliter) exhibited a similar antiaggregating effect, especially when secured from anemic patients.
No takes yet. Share an insight, caveat, or question.
Iatridis et al. (1975) studied Platelet aggregation. 2,3-Diphosphoglycerate (2,3-DPG) was evaluated on Platelet release reaction and irreversible aggregation. 2,3-Diphosphoglycerate (2,3-DPG) inhibited the platelet release reaction and irreversible aggregation of human blood platelets, with more pronounced effects in cases with low hematocrit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: